Logo image of MRVI

MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:MRVI - US56600D1072 - Common Stock

3.83 USD
+0.08 (+2.13%)
Last: 1/21/2026, 4:30:02 PM
3.83 USD
0 (0%)
After Hours: 1/21/2026, 4:30:02 PM

MRVI Key Statistics, Chart & Performance

Key Statistics
Market Cap979.37M
Revenue(TTM)192.28M
Net Income(TTM)-121.24M
Shares255.71M
Float106.43M
52 Week High6.05
52 Week Low1.67
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.3
PEN/A
Fwd PEN/A
Earnings (Next)03-16
IPO2020-11-20
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
MRVI short term performance overview.The bars show the price performance of MRVI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40

MRVI long term performance overview.The bars show the price performance of MRVI in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of MRVI is 3.83 USD. In the past month the price increased by 11.66%. In the past year, price decreased by -31.85%.

MARAVAI LIFESCIENCES HLDGS-A / MRVI Daily stock chart

MRVI Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to MRVI. When comparing the yearly performance of all stocks, MRVI is a bad performer in the overall market: 78.67% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

MRVI Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MRVI. While MRVI seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MRVI Financial Highlights

Over the last trailing twelve months MRVI reported a non-GAAP Earnings per Share(EPS) of -0.3. The EPS decreased by -900% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -14.28%
ROE -49.4%
Debt/Equity 1.29
Chartmill High Growth Momentum
EPS Q2Q%-300%
Sales Q2Q%-36.15%
EPS 1Y (TTM)-900%
Revenue 1Y (TTM)-30.56%

MRVI Forecast & Estimates

17 analysts have analysed MRVI and the average price target is 4.01 USD. This implies a price increase of 4.63% is expected in the next year compared to the current price of 3.83.

For the next year, analysts expect an EPS growth of -219.91% and a revenue growth -28.9% for MRVI


Analysts
Analysts76.47
Price Target4.01 (4.7%)
EPS Next Y-219.91%
Revenue Next Year-28.9%

MRVI Ownership

Ownership
Inst Owners76.87%
Ins Owners5.54%
Short Float %10.86%
Short Ratio8.47

MRVI Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 28.41 239.06B
DHR DANAHER CORP 31.39 170.97B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28 195.4 59.38B
IQV IQVIA HOLDINGS INC 20.76 41.11B
A AGILENT TECHNOLOGIES INC 25.05 39.62B
MTD METTLER-TOLEDO INTERNATIONAL 34.49 29.48B
WAT WATERS CORP 31.24 23.62B
ILMN ILLUMINA INC 34.97 23.30B
WST WEST PHARMACEUTICAL SERVICES 36.09 18.36B
MEDP MEDPACE HOLDINGS INC 43.4 17.48B
RVTY REVVITY INC 24.33 13.21B
TEM TEMPUS AI INC N/A 11.62B

Related stock screener links

About MRVI

Company Profile

MRVI logo image Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 550 full-time employees. The company went IPO on 2020-11-20. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. The company serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Company Info

MARAVAI LIFESCIENCES HLDGS-A

10770 Wateridge Circle Suite 200, Suite 200

San Diego CALIFORNIA 92121 US

CEO: Carl Hull

Employees: 580

MRVI Company Website

MRVI Investor Relations

Phone: 18585460004

MARAVAI LIFESCIENCES HLDGS-A / MRVI FAQ

What does MARAVAI LIFESCIENCES HLDGS-A do?

Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 550 full-time employees. The company went IPO on 2020-11-20. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. The company serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.


What is the current price of MRVI stock?

The current stock price of MRVI is 3.83 USD. The price increased by 2.13% in the last trading session.


What is the dividend status of MARAVAI LIFESCIENCES HLDGS-A?

MRVI does not pay a dividend.


What is the ChartMill rating of MARAVAI LIFESCIENCES HLDGS-A stock?

MRVI has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What sector and industry does MARAVAI LIFESCIENCES HLDGS-A belong to?

MARAVAI LIFESCIENCES HLDGS-A (MRVI) operates in the Health Care sector and the Life Sciences Tools & Services industry.


Can you provide the PE ratio for MRVI stock?

MARAVAI LIFESCIENCES HLDGS-A (MRVI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.3).


Can you provide the number of employees for MARAVAI LIFESCIENCES HLDGS-A?

MARAVAI LIFESCIENCES HLDGS-A (MRVI) currently has 580 employees.